Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): The 5-year update from the IRIS study

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Author(s): Druker BJ, Guilhot F, O'Brien SG, Larson RA, IRIS

Publication type: Conference Proceedings (inc. Abstract)

Publication status: Published

Conference Name: 42nd Annual Meeting of the American Society of Clinical Oncology

Year of Conference: 2006

Pages: 338S-338S

Publisher: Journal of Clinical Oncology: American Society of Clinical Oncology

Library holdings: Search Newcastle University Library for this item

ISBN:

ePrints